Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

Results demonstrate significant reductions in LDL-C, hsCRP and cardiovascular risk in patients who are unable to maximize or tolerate a statin

News | Pharmaceuticals

Landmark CLEAR Outcomes Study Demonstrates NEXLETOL (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population

April 3, 2023 — Esperion announced the full results from the landmark Cholesterol Lowering via Bempedoic acid, an ACL ...

April 03, 2023

Clearance of the IND will pave the way for the Company to initiate its randomized controlled Phase 1/2a MOJAVE study in the US, planned for Q2 2023

News | Pharmaceuticals

Sequana Medical Announces Submission of Investigational New Drug (IND) Application for DSR 2.0 for Treatment of Congestive Heart Failure

April 3, 2023 — Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and ...

April 03, 2023

A joint team of researchers from POSTECH and Georgia Institute of Technology successfully created an engineered heart via 3D printing technology that allows for early monitoring of drug-induced cardiotoxicity

News | Medical 3-D Printing

In Vitro 3D Engineered Heart Tissue that Monitors Drug-induced Cardiotoxicity

March 29, 2023 — Cardiotoxicity is a clinical condition that arises from using pharmaceutical agents such as antibiotics ...

March 29, 2023

PH-HFpEF affects more than 1,600,000 North Americans, with estimates indicating a prevalence of more than 2,000,000 patients by 2030

News | Cardiovascular Clinical Studies

Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

March 27, 2023 — Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and ...

March 27, 2023

The recalled product is used as an oral anticoagulant to lower the risk of stroke and blood clots.

News | Antiplatelet and Anticoagulation Therapies

Ascend Laboratories Issues Voluntary Nationwide Recall of Dabigatran Etexilate Capsules Due to the Detection of NDMA Impurity

March 24, 2023 — According to the U.S. Food and Drug Administration (FDA), Ascend Laboratories LLC is voluntarily ...

March 24, 2023

New Patent Adds to the Istaroxime Patent Estate and Provides Intellectual Property Protection Until Late 2039

News | Cardiogenic Shock

Windtree Therapeutics Announces Issuance of New Istaroxime Patent from U.S. Patent and Trademark Office

March 22, 2023 — Windtree Therapeutics, Inc., a biotechnology company focused on advancing multiple late-stage ...

March 22, 2023

US hospital claims data reveals cardiogenic shock patients have an average hospital length of stay of 19.6 days making its intensive patient care cost very high

News | Cardiogenic Shock

Windtree Finds Cardiogenic Shock Has High Cost of US Patient Care and Plans Innovation with the Unique Profile of Istaroxime

March 15, 2023 — Windtree Therapeutics, Inc, a biotechnology company focused on advancing late-stage interventions for ...

March 15, 2023

Kelly Chin, MD, professor of medicine and director of the pulmonary hypertension program at UT Southwestern Medical Center in Dallas

News | Hypertension

Fixed-Dose Combination Pill Outperforms Monotherapy for Pulmonary Hypertension

March 6, 2023 — Patients with pulmonary arterial hypertension (high blood pressure in the arteries that supply the lungs ...

March 06, 2023

Neha J. Pagidipati, MD, MPH, associate professor of medicine in cardiology at Duke University School of Medicine and Duke Clinical Research Institute

News | Cardiovascular Clinical Studies

Multifaceted Strategy Boosts Preventive Care for Diabetes, Heart Disease

March 6, 2023 — A multifaceted intervention to improve prescribing practices increased the likelihood that patients with ...

March 06, 2023

Presentations on Additional REDUCE-IT Sub-Population, In-Vitro Data on EPA to Be Featured at the Congress

News | Pharmaceuticals

Amarin Corp. to Present New Data Evaluating Vascept/Vazkepa (Icosapent Ethyl) at ACC23/WCC

February 27, 2023 — Amarin Corporation plc announced that data evaluating the role of VASCEPA /VAZKEPA (icosapent ethyl) ...

February 27, 2023

Edwards Lifesciences identified the top data releases from 2022 that contributed most to shaping awareness about the extent and impact of underdiagnosis and undertreatment of aortic stenosis (AS).

News | Stroke

Preventing Millions of Strokes and Heart Attacks Doesn’t Have to Come with the Risk of Life-threatening Bleeding

December 14, 2022 — Verseon announced that the European Journal of Medicinal Chemistry has published a paper describing ...

December 14, 2022

News | Cardiovascular Clinical Studies

Ninerafaxstat Showcased at the 19th Annual Global Cardio Vascular Clinical Trialists (CVCT) Forum with Focus on the Potential in Non-obstructive Hypertrophic Cardiomyopathy

December 9, 2022 — Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies ...

December 09, 2022

Bempedoic acid becomes the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse cardiovascular events (MACE-4) primary endpoint

News | Cardiovascular Clinical Studies

Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL (bempedoic acid) Meets Primary Endpoint

December 8, 2022 — Esperion announced that the landmark Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regim ...

December 08, 2022

Tanya Therapeutics announced today that the US FDA has granted orphan drug designation for its second gene therapy product candidate, TN-401, for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC)

News | Pharmaceuticals

Tenaya Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Gene Therapy for Genetic Arrhythmogenic Right Ventricular Cardiomyopathy

November 28, 2022 – Tenaya Therapeutics, a clinical-stage biotechnology company with a mission to discover, develop and ...

November 28, 2022

Reduction in the risk of death or major bleeding after primary PCI in patients with STEMI treated with heparin monotherapy (blue curve) or bivalirudin with a post-procedure infusion (red curve). The hazard ratio of 0.69 signifies a 31% reduction in risk. The ARR (absolute risk reduction) was 1.3%. The NNT (number of patients needed to treat to prevent one death or large bleed) was 76. Image courtesy of Mount Sinai Health System

News | Antiplatelet and Anticoagulation Therapies

Bivalirudin Found to be Safer and More Effective Than Heparin for Treating Heart Attack Patients Undergoing Percutaneous Coronary Intervention

November 14, 2022 — Bivalirudin is a safer and more effective anticoagulant than heparin for treating patients with the ...

November 14, 2022